Biodesix Future Growth
Future criteria checks 1/6
Biodesix is forecast to grow earnings and revenue by 35.9% and 19.7% per annum respectively while EPS is expected to grow by 47.6% per annum.
Key information
35.9%
Earnings growth rate
47.6%
EPS growth rate
Healthcare earnings growth | 20.7% |
Revenue growth rate | 19.7% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
Nov 21Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
Sep 24Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
Jun 12With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
Mar 03Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Jan 04It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
Jul 16A Second Look At Biodesix
Oct 18Biodesix expects Q3 revenue above the consensus
Oct 11Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M
Aug 04Biodesix: Bad Diagnosis
May 26Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher
Mar 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 113 | -26 | -7 | -11 | 3 |
12/31/2025 | 92 | -34 | -18 | -17 | 6 |
12/31/2024 | 71 | -45 | -53 | -55 | 6 |
9/30/2024 | 66 | -44 | -62 | -57 | N/A |
6/30/2024 | 61 | -45 | -61 | -50 | N/A |
3/31/2024 | 55 | -47 | -46 | -30 | N/A |
12/31/2023 | 49 | -52 | -46 | -23 | N/A |
9/30/2023 | 44 | -63 | -45 | -23 | N/A |
6/30/2023 | 42 | -66 | -46 | -29 | N/A |
3/31/2023 | 41 | -69 | -50 | -40 | N/A |
12/31/2022 | 38 | -65 | -49 | -45 | N/A |
9/30/2022 | 36 | -58 | -45 | -43 | N/A |
6/30/2022 | 31 | -56 | -43 | -41 | N/A |
3/31/2022 | 32 | -52 | -32 | -30 | N/A |
12/31/2021 | 55 | -43 | -31 | -28 | N/A |
9/30/2021 | 74 | -34 | -29 | -27 | N/A |
6/30/2021 | 77 | -32 | -26 | -23 | N/A |
3/31/2021 | 69 | -29 | -31 | -28 | N/A |
12/31/2020 | 46 | -31 | -24 | -21 | N/A |
9/30/2020 | 27 | -33 | -22 | -18 | N/A |
6/30/2020 | 22 | -34 | -23 | -21 | N/A |
3/31/2020 | 23 | -33 | -23 | -21 | N/A |
12/31/2019 | 25 | -31 | -24 | -22 | N/A |
12/31/2018 | 20 | -26 | -18 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDSX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BDSX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BDSX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BDSX's revenue (19.7% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: BDSX's revenue (19.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDSX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/30 16:39 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biodesix, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Sung Ji Nam | BTIG |
Kyle Mikson | Canaccord Genuity |
William Bonello | Craig-Hallum Capital Group LLC |